However, the discriminative potency of adropin for AF in individuals with HFpEF remains unclear and requires face-to-face comparison with conventionally used and promising biomarkers, such as natriuretic peptides, cardiac troponins, soluble suppression of tumorigenicity-2 and galectin-3. Here, LGALS3 is linked to atrial fibrillation.